(WSJ) – Moderna got a shot in the arm Wednesday after reporting that its personalized melanoma vaccine succeeded, in a large late-stage trial, at preventing cancer from coming back in high-risk patients. Investors cheered, as the company’s stock soared 177%. … Read More